WO2023166891A1

WO2023166891A1 - Composition for oral cavities

Info

Publication number: WO2023166891A1
Application number: PCT/JP2023/002501
Authority: WO
Inventors: 和夫田嶋; 洋子今井; 佳那宮坂; 和也山下; 悟長瀬
Original assignee: 学校法人神奈川大学; 悠香ホールディングス株式会社
Priority date: 2022-03-01
Filing date: 2023-01-26
Publication date: 2023-09-07
Also published as: JP2023127454A; TW202341968A; JP7144019B1

Abstract

This composition for oral cavities comprises an oily phase containing an oily antibacterial component, an aqueous phase, and at least one of a closed vesicle formed from an amphipathic substance capable of spontaneously forming a closed vesicle and a particle of a polycondensable polymer having a hydroxyl group, and is in the form of an O/W-type emulsion.

Description

oral composition

The present invention relates to an oral composition.

Various bacteria and fungi exist in the oral cavity, and biofilms are formed by these multiple oral bacteria. Insufficient care of this biofilm has been found to have adverse effects not only on periodontal disease and bad breath, but also on the whole body. Under these circumstances, it is required to take measures against bacteria and fungi present in the oral cavity.

For example, in Patent Document 1, one or two selected from menthol (B), thymol (C-1) and carvacrol (C-2) while containing an oil agent (A) that is liquid at 25 ° C. A two-layer separation type liquid obtained by separating two layers, an oil layer containing the above and one or more components (D) selected from rose, lavender, chamomile, jasmine, orris and violet, and an aqueous layer. An oral composition is described.

Further, Patent Document 2 discloses an oil phase containing one or more antimicrobial essential oils, a solvent system containing at least one polyol solvent and at least one sugar alcohol solvent, and at least one alkyl sulfate surfactant. , optionally at least one additional surfactant, and an aqueous phase comprising water are described. The ratio of oil phase to solvent system to alkyl sulfate surfactant in the antimicrobial mouthrinse composition is on the order of 1:60:1.5 by weight.

In addition to oral use, for the purpose of suppressing the growth of fungi present in the intestines of livestock, closed endoplasmic reticulum of amphiphilic substances formed by spontaneous self-organization and medium-chain fatty acids are added to the aqueous phase. and medium-chain fatty acid monoglyceride, is maintained in an acidic region, and the oil component is maintained in an emulsified state by intervening the closed endoplasmic reticulum at the interface between the aqueous phase and the oil droplet phase of the oil component. Patent Document 3 describes an emulsified acidic composition for livestock that

Also, it is used by applying to the skin, the internal phase is an oil phase, the external phase is an aqueous phase, and a closed vesicle formed by an amphipathic substance that spontaneously forms a closed vesicle or a polymer having a hydroxyl group. Patent Document 4 describes an antiperspirant or deodorant which is of the O/W emulsion type containing condensation polymer particles and which further contains a deodorizing component.

JP 2014-051445 A JP 2012-012394 A JP 2015-131769 A JP 2016-104713 A

However, in a two-layer separated oral composition such as that of Patent Document 1, components that are difficult to mix are mixed. Therefore, with the passage of time, each component separates and the effect of the oral composition is reduced. Further, in the antibacterial mouthwash composition of Patent Document 2, a surfactant is used. In some cases, the surfactant content is higher than the oil phase content. Surfactants have problems such as strong irritation. In particular, since the oral composition is used in the oral cavity, palatability is required for the oral composition. Moreover, in order for the oral composition to exhibit stable antibacterial properties in the oral cavity over a long period of time, it is required to improve the retention of the oral composition in the oral cavity. In addition, if the oral composition contains alcohol, it is unsuitable for people with low alcohol tolerance. For example, the high solubility may reduce the retention of the oral composition. In addition, the emulsified acidic composition for livestock of Patent Document 3 is a technique for stably maintaining the emulsified state until it reaches the intestines, because the antibacterial component is directly put into the intestines of livestock, and the antiperspirant of Patent Document 4. A deodorant or deodorant is applied to the skin to improve the feeling of use and the adhesion of deodorant ingredients to the skin. Far away.

An object of the present invention is to provide an oral composition that has stable and excellent antibacterial properties, good palatability, and dispersibility and retention in the oral cavity.

[1] An oil phase containing an oily antibacterial component, an aqueous phase, and at least one of closed vesicles formed by an amphipathic substance that spontaneously forms closed vesicles and particles of a polycondensation polymer having a hydroxyl group. and is an O/W emulsion.
[2] The composition for oral cavity according to [1] above, wherein the content of the oil phase in the composition for oral cavity is 5.00×10 ⁻³ mass % or more and 80.00 mass % or less.
[3] The oral cavity according to [1] or [2] above, wherein the content of the oily antibacterial component in the oral cavity composition is 5.00 × 10 ^-3 mass% or more and 10.00 mass% or less. composition.
[4] The oil-based antibacterial component includes alkyl fatty acids having 6 to 16 carbon atoms, lower fatty acid monoglycerides, monoterpene hydrocarbons having a molecular weight of 600 or less, sesquiterpene hydrocarbons, diterpene hydrocarbons, monoterpene alcohols, sesqui from terpene alcohols, diterpene alcohols, phenols, ketones, terpene aldehydes, aliphatic aldehydes, aromatic aldehydes, phenol ethers, lactones, esters, ethers, oxides, carboxylic acids and organic acids The oral composition according to any one of [1] to [3] above, which is one or more antibacterial ingredients selected from the group consisting of:

According to the present invention, it is possible to provide an oral composition that has stable and excellent antibacterial properties, good palatability, and dispersibility and retention in the oral cavity.

FIG. 1 is a photograph of the apatite plate stained in Example 7-1 taken with a digital camera. FIG. 2 is a photograph taken with a digital camera of the apatite plate stained in Comparative Example 7-1. FIG. 3 is a photograph taken with a digital camera of the apatite plate stained in Comparative Example 7-2.

A detailed description will be given below based on the embodiment.

As a result of extensive research, the present inventors have found that by applying a three-phase emulsification technology that is completely different from the emulsification mechanism of surfactants to emulsify oily antibacterial ingredients, dispersibility and retention in the oral cavity can be improved. , Since emulsified particles (three-phase emulsified particles) containing an oily antibacterial component are stably dispersed in the aqueous phase, excellent antibacterial properties can be stably exhibited for a long period of time. The present inventors have found that palatability can be improved compared to an oral composition using an active agent, and have completed the present disclosure based on this finding.

The oral composition of the embodiment includes an oil phase containing an oily antibacterial component, an aqueous phase, and a closed endoplasmic reticulum formed by an amphiphilic substance that spontaneously forms a closed endoplasmic reticulum (hereinafter, also simply closed endoplasmic reticulum and at least one of polycondensation polymer particles having hydroxyl groups (hereinafter also simply referred to as polycondensation polymer particles), and is an O/W emulsion. The oral composition is a composition to which a so-called three-phase emulsification method using closed endoplasmic reticulum or polycondensation polymer particles is applied.

At least one of the closed endoplasmic reticulum and polycondensation polymer particles exists around the oil phase containing the oily antibacterial component, and the aqueous phase exists outside of them. That is, at least one of a plurality of closed vesicles and polycondensation polymer particles is present at the interface between the oil phase containing the oily antibacterial component and the water phase, and the water phase is the continuous phase. Thus, the oral composition is an O/W emulsion in which an oil phase containing an oily antimicrobial component is dispersed in an aqueous phase.

The oral composition contains a large number of emulsified particles (three-phase emulsified particles) in which at least one of the closed endoplasmic reticulum and polycondensation polymer particles exists around a particulate oil phase (hereinafter also referred to as oil droplets). do. An aqueous phase exists around emulsified particles containing an oily antibacterial component, and a large number of emulsified particles are dispersed in the aqueous phase.

A closed endoplasmic reticulum formed by an amphiphilic substance that spontaneously forms a closed endoplasmic reticulum has the property of spontaneously forming a closed endoplasmic reticulum in an aqueous component. Particles of closed vesicles and polycondensation polymers are known as particles with so-called three-phase emulsifying ability. Since the surfaces of the closed vesicles and the particles of the polycondensation polymer are hydrophilic, the closed vesicles and the particles of the polycondensation polymer generate mutual repulsion.

A large number of closed vesicles and polycondensation polymer particles are present on the surface of the oil phase containing the oily antibacterial component. , a repulsive force is generated between the oil phases containing the oily antibacterial component. The repulsive force generated between the oil phases is greater than the attractive force generated between the oil phases. Therefore, aggregation of the oil phase containing the oily antibacterial component in the aqueous phase, in other words, aggregation of the emulsion particles is suppressed, and the dispersibility of the oil phase containing the oily antibacterial component is maintained and improved.

In such a three-phase emulsification method, particles of closed endoplasmic reticulum and polycondensation polymer are present at the interface between the oil phase and the water phase, and adhere to the oil phase by Van der Waals force to enable emulsification. It is something to do. The three-phase emulsification mechanism is completely different from the surfactant-based emulsification mechanism in which the hydrophilic part and the hydrophobic part are directed to the water phase and the oil phase, respectively, and the emulsified state is maintained by lowering the oil-water interfacial tension (for example, Japanese Patent No. 3855203 (see publication). In the oral composition of the embodiment, as described above, the closed endoplasmic reticulum and polycondensation polymer particles emulsify the oil phase containing the oily antibacterial component.

In the oral composition, at the interface between the oil phase and the aqueous phase, only a plurality of closed vesicles may be present, only a plurality of polycondensation polymer particles may be present, or a plurality of closed vesicles may be present. Cellular bodies and particles of a plurality of polycondensation polymers may be intermingled.

The oily antibacterial component contained in such an oral composition is oily. When an oral composition comprising only an oil-based antimicrobial component, that is, only an oil-based antimicrobial component is used in the oral cavity, the oil-based antimicrobial component does not readily disperse in saliva, and in some cases separates from saliva. Therefore, the antibacterial properties of the oily antibacterial component are not sufficiently exhibited throughout the oral cavity. Furthermore, palatability of an oral composition consisting only of an oily antibacterial component is poor. On the other hand, in the oral composition of the embodiment, the oily antibacterial component is dispersed in the aqueous phase in the form of emulsified particles. Even when the oral composition is used in the oral cavity, the oily antibacterial component dispersed in the aqueous phase can maintain good dispersibility even in saliva. In particular, the dispersibility of the composition for oral cavity in saliva when gargling is excellent. Therefore, the oral composition can stably have excellent antibacterial properties throughout the oral cavity.

Furthermore, the oral composition uses a three-phase emulsification technology that is completely different from the emulsification mechanism by surfactants. The oral composition can contain substantially less surfactant, and in some cases, no surfactant, as compared to compositions using conventional surfactants. That is, it is possible to suppress the decrease in palatability derived from the surfactant. As such, the oral composition can have good palatability.

Furthermore, the oral composition contains emulsified particles formed by three-phase emulsification. Emulsified particles formed by three-phase emulsification have a stronger adsorptive power to surfaces of substances such as tooth surfaces and mucosal surfaces than compositions using conventional surfactants. Even if an external force acts on the emulsified particles containing the oily antibacterial component, the emulsified particles are less likely to be detached from the surface of the oral cavity, and the composition for oral cavity is excellent in retention in the oral cavity. Therefore, the oral composition has stable antibacterial properties in the oral cavity for a long period of time. In addition, since the oral composition of the embodiment can coexist with an aqueous antibacterial component, it is excellent in cleaning the oral cavity.

In addition, as described above, since the oral composition has excellent dispersibility and retention in the oral cavity, it is difficult for bacteria to propagate in the oral cavity. Thus, the composition for oral cavity can suppress the propagation of bacteria in the oral cavity over a long period of time.

In addition, even without using alcohol such as ethanol, the oil-based antibacterial component is stably dispersed in the aqueous phase. As such, the amount of alcohol can be significantly reduced, and in some cases alcohol-free, compared to conventional alcohol-containing oral compositions. Therefore, the oral composition of the embodiment can be used satisfactorily even by people with low alcohol tolerance, and can suppress the adverse effect of alcohol on taste and the deterioration of retention of the oral composition.

The oil phase in the oral composition contains an oily antibacterial component. The oil phase may consist only of the oily antibacterial component, or may contain other oily components in addition to the oily antibacterial component.

The oil-based antibacterial ingredient has antibacterial properties against fungi and bacteria that exist in the oral cavity, regardless of whether they are aerobic or anaerobic. Preferably, the oleaginous antimicrobial component has antimicrobial properties against Candida and E. coli. From the viewpoint of having excellent antibacterial properties, oil-based antibacterial ingredients include alkyl fatty acids with 6 to 16 carbon atoms, lower fatty acid monoglycerides, monoterpene hydrocarbons with a molecular weight of 600 or less, sesquiterpene hydrocarbons, diterpene hydrocarbons, mono Terpene alcohols, sesquiterpene alcohols, diterpene alcohols, phenols, ketones, terpene aldehydes, aliphatic aldehydes, aromatic aldehydes, phenol ethers, lactones, esters, ethers, oxides, carvone It is preferably one or more antibacterial ingredients selected from the group consisting of acids and organic acids. Caprylic acid and capric acid are preferable as the alkyl fatty acid having 6 to 16 carbon atoms. Preferred lower fatty acid monoglycerides are caprylic acid glycerides and capric acid glycerides. Preferred monoterpene hydrocarbons having a molecular weight of 600 or less are limonene and terpinene. Farnesene is preferred as the sesquiterpene hydrocarbon. Geranylgeraniol is preferred as the diterpene hydrocarbon. Preferred monoterpene alcohols are menthol and nerol. Preferred sesquiterpene alcohols are nerolidol and patchouli alcohol. The diterpene alcohols are preferably cinnamic alcohols. As phenols, thymol is preferred. Preferred ketones are acetophenone and camphor. Preferred terpene aldehydes are citronellal and geranial. Preferred aliphatic aldehydes are n-octal and n-decanal. Cinnamaldehyde is preferred as the aromatic aldehyde. Preferred phenol ethers are anethole and methyl eugenol. As the lactones, allan lactone is preferred. Preferred esters are methyl benzoate, ethyl benzoate and methyl salicylate. The ether is preferably glycerin mono-2-ethylhexyl ether. The oxides are preferably cineol. Preferred carboxylic acids and organic acids are cinnamic acid and benzoic acid.

When the oil phase contains other oily components in addition to the oily antibacterial component, the other oily components are not particularly limited, and both solid oil and liquid oil are suitable. Solid oil is oil that is solid at room temperature (25° C.), and liquid oil is oil that is liquid at room temperature.

The other oily component may be solid oil alone, liquid oil alone, or a mixture of solid and liquid oils. The more solid oil, the less fluid the oral composition, and the more liquid oil, the more fluid the oral composition. The content ratio of the solid oil and the liquid oil is appropriately selected according to the use of the oral composition.

The solid oil is not particularly limited as long as it is a solid oil at room temperature. , waxes, higher alcohols (behenyl alcohol, stearyl alcohol, cetyl alcohol, batyl alcohol, etc.), waxes (carnauba wax, beeswax, etc.), and the like.

The liquid oil is not particularly limited as long as it is liquid at room temperature. oil, cottonseed oil, soybean oil, teaseed oil, rice bran oil, wheat germ oil, germ oil, peanut oil, sunflower oil, almond oil, turtle oil, corn oil, mink oil, persic oil, sasanqua oil, linseed oil, enno oil , kaya oil, etc.), animal oils (beef tallow, lard, milk fat, etc.), medium-chain fatty acid triglycerides, hydrocarbon oils (squalene, squalane, liquid paraffin, etc.), ester oils (cetyl ethylhexanoate, diisostearyl malate, myristin) Isopropyl acid, ethylhexyl palmitate, octyl palmitate, octyl isopalmitate, isononyl isononanoate, isotridecyl isononanoate, methylheptyl laurate, hexyl laurate, caprylic/capric triglyceryl, triethylhexanoin, neo dicaprate Pentyl recall, cetyl octanoate, isocetyl stearate, isopropyl isostearate, isodecyl oleate, glyceryl tri-2-ethylhexanoate, pentaerythrityl tetra-2-ethylhexanoate, 2-ethylhexyl succinate, diethyl sebacate, etc.), wax (jojoba oil), higher alcohol (octyldodecanol, oleyl alcohol, isostearyl alcohol) silicone oil (cyclopentasiloxane, decamethylcyclopentasiloxane, methylpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane) , octamethylcyclotetrasiloxane, dodecamethylcyclohexasiloxane, etc.), fluorine oil, and the like.

Among the above, the other oily component is preferably a medium-chain fatty acid triglyceride from the viewpoint of oral cavity use, solubility, fluidity, and palatability for the oily antibacterial component.

The content ratio of the oil phase and the oily antibacterial component contained in the oral composition is appropriately selected according to the use of the oral composition.

For example, the content of the oil phase contained in the oral cavity composition is 5.00×10 ⁻³ mass % or more and 80.00 mass % or less. When the content of the oil phase is within the above range, the dispersibility in the oral cavity is good.

5. The content of the oily antibacterial component in the oral cavity composition is preferably 5.00×10 ⁻³ mass % or more, more preferably 1.00×10 ⁻² mass % or more. More preferably, it is 00×10 ⁻² mass % or more. When the content of the oily antibacterial component is 5.00×10 ⁻³ mass % or more, the antibacterial properties are good. In addition, the content of the oily antibacterial component contained in the oral cavity composition is preferably 10.00% by mass or less, more preferably 5.00% by mass or less, and 1.00% by mass or less. is more preferred. When the content of the oily antibacterial component is 10.00% by mass or less, a decrease in palatability can be suppressed.

The average particle size of the oil phase containing the oily antibacterial component is appropriately selected according to the use of the oral composition. Since the oral composition is based on three-phase emulsification, the average particle size of the oil phase containing the oily antibacterial component can be selected within a wider range than conventional emulsified compositions using surfactants. can be done. For example, the average particle size of the oil phase containing the oily antibacterial component is preferably 0.1 µm or more, more preferably 1.0 µm or more, and even more preferably 10.0 µm or more. Also, the average particle size of the oil phase containing the oily antibacterial component is preferably 100.0 μm or less, more preferably 50.0 μm or less, and even more preferably 30.0 μm or less. When the average particle size of the oil phase containing the oil-based antibacterial component is 0.1 μm or more, the oil-based antibacterial component efficiently acts against bacteria such as Candida, resulting in good antibacterial properties of the oral composition. be. Moreover, when the average particle diameter of the oil phase containing the oily antibacterial component is 100.0 μm or less, the dispersibility of the oil phase is good, so that the composition for oral cavity has good antibacterial properties. The average particle size of the oil phase is a value determined by Contin analysis after measuring by a dynamic light scattering method using a particle size distribution analyzer FPAR (manufactured by Otsuka Electronics Co., Ltd.).

The oil phase may contain ingredients such as tea leaves, polyphenols, peptide substances, scrubbing agents, powders, and fragrances in addition to the oily antibacterial ingredients and other oily ingredients.

The aqueous phase in the oral composition is an aqueous component and is immiscible with the oil phase. The aqueous phase is the continuous phase and disperses a plurality of emulsified particles. The aqueous phase is preferably water such as purified water, or water containing polyhydric alcohols such as glycerin, butylene glycol, and sorbitol.

The total amount of the aqueous phase in the oral composition is appropriately selected according to the use of the oral composition. For example, the total amount of the aqueous phase is preferably 20.000% by mass or more, 30.000% by mass or more, 40.000% by mass or more, and 50.000% by mass or more with respect to the total amount of the oral composition. Increasingly more favorable. Further, the total amount of the aqueous phase is preferably 99.995% by mass or less, 90.000% by mass or less, 80.000% by mass or less, and 70.000% by mass or less with respect to the total amount of the oral composition. Decreasing is more favorable. When the total amount of the aqueous phase is 40.000% by mass or more, the dispersibility of the oil phase containing the oily antibacterial component in the oral cavity is good, so that the oral cavity composition has good antibacterial properties. In addition, when the total amount of the aqueous phase is 99.995% by mass or less, the oral composition contains an oily antibacterial component in an amount that can antibacterially kill bacteria present in the oral cavity. Good characteristics.

The aqueous phase may contain ingredients such as tea leaves, polyphenols, peptide substances, scrubbing agents, powders, flavors, and artificial sweeteners.

Regarding the closed endoplasmic reticulum in the oral composition, the amphiphilic substance that spontaneously forms the closed endoplasmic reticulum (hereinafter simply referred to as amphiphilic substance) is polyoxyethylene curing represented by the following formula (1) It is preferably a derivative of castor oil.

In formula (1), E (E=L+M+N+X+Y+Z), which is the average number of added moles of ethylene oxide, is preferably 3 or more and 100 or less.

In addition to the above, preferred examples of amphiphilic substances include those in which a hydrophobic group and a hydrophilic group are ester-bonded, such as phospholipids and phospholipid derivatives.

As the phospholipid, among the structures represented by the following formula (2), DLPC with a carbon chain length of 12 (1,2-Dilauroyl-sn-glycero-3-phospho-rac-1-choline), a carbon chain length of 14 DMPC (1,2-Dimyristoyl-sn-glycero-3-phospho-rac-1-choline), DPPC with a carbon chain length of 16 (1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-1-choline ) is preferred. Further, lipids having glycerin or sphingosine as a central skeleton and fatty acids bound thereto and having a phosphate site and a choline site in the structure are preferable.

Further, among the structures represented by the following formula (3), Na salt or NH ₄ salt of DLPG (1,2-Dilauroyl-sn-glycero-3-phospho-rac-1-glycerol) having a carbon chain length of 12, Na salt or _NH4 salt of DMPG with a carbon chain length of 14 (1,2-Dimyristoyl-sn-glycero-3-phospho-rac-1-glycerol), DPPG with a carbon chain length of 16 (1,2-Dipalmitoyl-sn- Na or NH ₄ salt of glycero-3-phospho-rac-1-glycerol) is preferred.

Furthermore, preferred examples of phospholipids include lecithins such as egg yolk lecithin and soybean lecithin.

Suitable examples of amphiphilic substances include fatty acid esters. Suitable fatty acid esters include glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, and propylene glycol fatty acid esters.

The polyglycerin fatty acid ester is a straight-chain or branched fatty acid, regardless of whether the fatty acid is saturated or unsaturated, and is preferably an ester of the fatty acid and polyglycerin. Among them, polyglyceryl monomyristate and dimyristate Polyglyceryl, polyglyceryl trimyristate, polyglyceryl monopalmitate, polyglyceryl dipalmitate, polyglyceryl tripalmitate, polyglyceryl monostearate, polyglyceryl distearate, polyglyceryl tristearate, polyglyceryl monoisostearate, polyglyceryl diisostearate, polyglyceryl triisostearate, More preferred are polyglyceryl monooleate, polyglyceryl dimonooleate, and polyglyceryl trimonooleate, and even more preferred is decaglyceryl myristate.

As the sucrose fatty acid ester, sucrose laurate, sucrose myristate, sucrose palmitate, sucrose stearate, and sucrose oleate are preferable.

Regarding the polycondensation polymer particles in the oral composition, the polycondensation polymer having a hydroxyl group (hereinafter also simply referred to as polycondensation polymer) may be a natural polymer, a synthetic polymer, or a semi-synthetic polymer. It is appropriately selected according to the use of the composition. Among them, the polycondensation polymer is preferably a natural polymer from the viewpoint of excellent safety and generally inexpensive, and more preferably a sugar polymer from the viewpoint of excellent emulsifying function.

Particles of the polycondensation polymer include single particles of the polycondensation polymer and those in which the single particles of the polycondensation polymer are connected to each other. have) are not included.

Sugar polymers are polymers with glucoside structures such as cellulose and starch. For example, monosaccharides such as ribose, xylose, rhamnose, fucose, glucose, mannose, glucuronic acid, and gluconic acid, which are produced by microorganisms using some sugars as constituents, xanthan gum, gum arabic, guar gum, karaya gum, and carrageenan , pectin, fucoidan, quinseed gum, tranto gum, locust bean gum, galactomannan, curdlan, gellan gum, fucogel, casein, gelatin, starch, collagen, hyaluronic acid, hyaluronic acid derivatives, natural polymers such as white fungus polysaccharide, methylcellulose , ethylcellulose, methylhydroxypropylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, propylene glycol alginate, cellulose crystals, starch-sodium acrylate graft polymer, hydrophobized hydroxypropylmethylcellulose, etc. Molecules, synthetic macromolecules such as polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymers, polyacrylates, polyethylene oxide are preferred.

The total amount of the closed endoplasmic reticulum and polycondensation polymer particles contained in the oral composition is preferably 0.001% by mass or more, preferably 0.002% by mass or more, relative to the total amount of the oil phase. is more preferably 0.005% by mass or more, and particularly preferably 0.01% by mass or more. In addition, the total amount of the closed endoplasmic reticulum and the particles of the polycondensation polymer is 50% by mass or less, 40% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less with respect to the total amount of the oil phase. % or less and 10% by mass or less. When the total amount of the closed vesicles and polycondensation polymer particles is within the above numerical range, the closed vesicles and polycondensation polymer particles have excellent emulsifying properties, so that the oral composition has antibacterial properties and dispersion in the oral cavity. properties and staying power are further improved. The above amounts are solids contents.

The average particle size of the particles of the closed endoplasmic reticulum and the polycondensation polymer is 8 nm or more and 800 nm or less before emulsified particles are formed, but is 8 nm or more and 500 nm or less in the oral composition. The oral composition may contain only closed vesicles, may contain only particles of polycondensation polymer, or may contain closed vesicles and particles of polycondensation polymer. If the oral composition comprises closed vesicles and particles of a polycondensation polymer, for example, separately emulsified emulsions may be mixed to produce the oral composition. The average particle size of the particles of the closed endoplasmic reticulum and polycondensation polymer is a value determined by Contin analysis after measuring by dynamic light scattering using a particle size distribution analyzer FPAR (manufactured by Otsuka Electronics Co., Ltd.). A method for preparing closed vesicles and polycondensation polymer particles having an average particle size within the above numerical range is conventionally known as a method for preparing particles having three-phase emulsifying ability, as disclosed in Japanese Patent No. 3855203 and the like. Therefore, it is omitted here for convenience.

In addition, light scattering measurement is performed on the mixed solution described later used for emulsifying the oily component, and the average particle size of the particles of the closed endoplasmic reticulum and the polycondensation polymer present in the mixed solution is, for example, 8 nm or more and 400 nm or less. , it can be concluded that the closed endoplasmic reticulum and the polycondensation polymer particles are capable of three-phase emulsification. Further, the emulsion contained in the oral composition is observed with an atomic force microscope (AFM) to confirm that at least one of the closed endoplasmic reticulum and the polycondensation polymer particles is attached to the surface of the oil phase. Thus, emulsified particles can be confirmed.

In addition to the above components, the oral cavity composition may also contain additional components such as thickeners, preservatives, cleaning agents (abrasives), and caking agents. From the viewpoint of exerting the effect of the additive component, the content of the additive component contained in the oral composition is preferably 0.01% by mass or more, more preferably 0.10% by mass or more. In addition, from the viewpoint of not reducing the good antibacterial properties, palatability, dispersibility and retention of the oral composition, the content of the additive component contained in the oral composition is preferably 20.00% by mass or less, and more Preferably, it is 10.00% by mass or less.

The form of the oral composition is appropriately selected, such as liquid or paste, depending on the use of the oral composition. The form of the oral composition can be adjusted according to the compositional ratio of the oil phase, aqueous phase, closed endoplasmic reticulum, and polycondensation polymer particles.

Such oral compositions are liquid, gel, and paste dentifrices and mouthwashes that are required to have stable and excellent antibacterial properties, good palatability, dispersibility and retention in the oral cavity. , wiping sheets, and pastes for sonic toothbrushes and electric toothbrushes.

Next, a method for producing the oral cavity composition will be described.

The method for producing an oral composition has a mixing step and an emulsifying step.

In the mixing step, at least one of closed vesicles formed by an amphiphilic substance that spontaneously forms closed vesicles and particles of polycondensation polymer having hydroxyl groups are mixed with an aqueous component to obtain a mixed solution. In the mixed solution, at least one of the plurality of closed vesicles and the plurality of polycondensation polymer particles are dispersed in the aqueous component.

For example, in the case of closed vesicles formed by an amphiphilic substance that spontaneously forms closed vesicles, in the mixing step, while stirring an aqueous component such as water with a stirrer or the like, a predetermined amount of the amphiphile is added. to the aqueous component to form a plurality of closed vesicles and mix the plurality of closed vesicles with the aqueous component. In the case of particles of a polycondensation polymer having a hydroxyl group, in the mixing step, while stirring the aqueous component with a stirrer or the like, a plurality of polycondensation polymer particles are added to the aqueous component to obtain a plurality of polycondensation polymers and Aqueous components are mixed.

When closed vesicles and polycondensation polymer particles are used, a solution in which closed vesicles are dispersed and a solution in which polycondensation polymer particles are dispersed may be mixed to produce a mixed solution. A medium and particles of polycondensation polymer may be added to the aqueous component to form a mixed solution.

In the emulsification process performed after the mixing process, the mixed solution obtained in the mixing process and the oily component having a melting point or higher are mixed to obtain an oral composition. The oily component contains an oily antibacterial component. The oral composition comprises a large number of emulsified particles in which the surfaces of oil droplets containing an oily antimicrobial component are coated with at least one of a plurality of closed vesicles and a plurality of polycondensation polymer particles. Emulsified particles containing an oily antimicrobial component are dispersed in an aqueous phase.

For example, by adding an oily component having a melting point or higher to the mixed solution while stirring the mixed solution with a stirrer or the like, emulsified particles are formed and an oral composition containing dispersed emulsified particles can be obtained. If the temperature of the oily component added to the mixed solution is lower than the melting point, it may be difficult to shear the oily agent, resulting in insufficient formation of emulsified particles. Therefore, when the temperature of the oil component to be added to the mixed solution is below the melting point, it is preferable to heat the oil component to the melting point or higher and then add the oil component having the melting point or higher to the mixed solution.

According to the embodiments described above, by emulsifying the oil-based antibacterial component with the three-phase emulsification technology, the oral composition has stable and excellent antibacterial properties, and is excellent in dispersibility and retention in the oral cavity. , can have good palatability.

Next, examples and comparative examples will be described, but the present invention is not limited to these examples.

(Examples 1-1 to 1-2 and Comparative Examples 1-1 to 1-4)
Cinnamaldehyde (manufactured by Nagaoka Koryo Co., Ltd.), an oil-based antibacterial component, and medium-chain fatty acid triglyceride (manufactured by Kao Corporation, Coconard MT), which is an oil-based component, are used as the oil phase, and water and particles of a polycondensed polymer having a hydroxyl group are used as the aqueous phase. Using particles of stearoxyhydroxypropyl methylcellulose (manufactured by Daido Kasei Kogyo Co., Ltd., Sunjurose 90L) as a powder, oral compositions having the composition ratio (% by mass) shown in Table 1 were produced. Specifically, by adding particles of stearoxyhydroxypropylmethylcellulose to water while stirring the water, a mixed solution in which a plurality of particles of stearoxyhydroxypropylmethylcellulose are dispersed in water was obtained. Subsequently, while stirring the mixed solution, cinnamaldehyde having a melting point or higher was added to the mixed solution to obtain an oral composition of Example 1-1. Further, while stirring the mixed solution, cinnamaldehyde and medium-chain fatty acid triglyceride having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 1-2.

Also, by mixing cinnamaldehyde and medium-chain fatty acid triglyceride at the composition ratio shown in Table 1, an oral composition of Comparative Example 1-1 was obtained.

Further, an oral composition of Comparative Example 1-2 was obtained by adding stearoxyhydroxypropylmethylcellulose to water at the composition ratio shown in Table 1 while stirring the water.

Further, at the composition ratio shown in Table 1, while stirring the water, stearoxyhydroxypropyl methylcellulose was added to the water, and then the medium-chain fatty acid triglyceride was added to obtain an oral composition of Comparative Example 1-3. Ta.

In addition, medium-chain fatty acid triglycerides were used as oral compositions of Comparative Examples 1-4.

The oral cavity compositions obtained in Examples 1-1 to 1-2 and Comparative Examples 1-1 to 1-4 were tested for their antibacterial activity against yeast-type Candida (C. albicans strain NBRC1594) as follows. evaluated.

The test medium (YPD medium (g/1000 ml), Polypepton 20 g, Yeast extract 10 g, Glucose 20 g) was adjusted to a final concentration of 100 µg/ml of the oral composition. Candida fungus was added to the YPD medium supplemented with the oral cavity composition so as to be 1.0×10 ⁵ cfu/ml. After that, culture was performed at 36° C. (pseudo temperature in the oral cavity) for 18 hours.

The turbidity of the suspension was measured using an absorptiometer (wavelength 620 nm). When the turbidity of the culture solution obtained by culturing Candida in YPD medium without adding the oral cavity composition was set to 100, the relative value of turbidity in each example and each comparative example was determined. Table 1 shows the results of relative values.

As shown in Table 1, Examples 1-1 and 1-2, in which the oil-based antibacterial component was three-phase emulsified, had good antibacterial properties and were able to suppress the growth of Candida. In addition, since the oil-based antibacterial ingredient was three-phase emulsified, the oil-based antibacterial ingredient had excellent intraoral dispersibility. Moreover, since the oral compositions of Examples 1-1 and 1-2 did not contain a surfactant, they were excellent in palatability. On the other hand, in Comparative Example 1-1, in which the oily antibacterial component is not three-phase emulsified, although the oily antibacterial component is contained, it is dissolved in the oily substance, so the dispersibility is poor. had little effect on the suppression of In Comparative Example 1-2, since no oil-based antibacterial component was contained, there was almost no effect on inhibiting the proliferation of Candida. In Comparative Examples 1-3, although the oily substance was three-phase emulsified and dispersible, it did not contain an oily antibacterial component, so it had almost no effect on the inhibition of the growth of Candida. Comparative Example 1-4 contained only oily ingredients and was not three-phase emulsified, resulting in poor dispersibility, and since it did not contain any oily antibacterial ingredients, it had almost no effect on inhibiting the growth of Candida. .

(Examples 2-1 to 2-2 and Comparative Examples 2-1 to 2-2)
As the oil phase, antibacterial capric acid (manufactured by Kao Corporation, Lunac 10-98) and other oil-based medium-chain fatty acid triglycerides (manufactured by Kao Corporation, Coconard MT). Using particles of stearoxyhydroxypropyl methylcellulose (Sunjurose 90L, manufactured by Daido Kasei Kogyo Co., Ltd.) as condensation polymer particles, an oral composition having a composition ratio (% by mass) shown in Table 2 was produced. Specifically, by adding particles of stearoxyhydroxypropylmethylcellulose to water while stirring the water, a mixed solution in which a plurality of particles of stearoxyhydroxypropylmethylcellulose are dispersed in water was obtained. Subsequently, while stirring the mixed solution, capric acid having a melting point or higher was added to the mixed solution to obtain an oral composition of Example 2-1. Further, while stirring the mixed solution, capric acid and medium-chain fatty acid triglyceride having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 2-2.

Also, an oral composition of Comparative Example 2-1 was obtained by mixing capric acid, medium-chain fatty acid triglycerides, and water at the composition ratio shown in Table 2.

In addition, capric acid was used for the oral cavity composition of Comparative Example 2-2.

The oral compositions obtained in Examples 2-1 to 2-2 and Comparative Examples 2-1 to 2-2 were evaluated for their antibacterial activity against Candida (C. albicans strain NBRC1594) as follows.

The test medium (YPD medium (g/1000 ml), Polypepton 20 g, Yeast extract 10 g, Glucose 20 g) was adjusted to a final concentration of 100 µg/ml of the oral composition. Candida fungus was added to the YPD medium supplemented with the oral cavity composition so as to be 1.0×10 ⁵ cfu/ml. After that, culture was performed at 36° C. for 18 hours, 24 hours and 72 hours.

The turbidity of the suspension was measured using an absorptiometer (wavelength 620 nm). When the turbidity of the culture solution obtained by culturing Candida in YPD medium without adding the oral cavity composition was set to 100, the relative value of turbidity in each example and each comparative example was determined. Table 2 shows the results of relative values.

As shown in Table 2, as in Examples 1-1 and 1-2, Examples 2-1 and 2-2, in which the oil-based antibacterial component was three-phase emulsified, also had good antibacterial properties, so Candida fungi growth could be suppressed. In addition, even when the oily antibacterial component was capric acid, it exhibited good antibacterial properties. In addition, since the oily antibacterial component was three-phase emulsified, the oral cavity dispersibility and retention of the oily antibacterial component were excellent. Moreover, since the oral compositions of Examples 2-1 and 2-2 did not contain a surfactant, they were excellent in palatability. On the other hand, in Comparative Examples 2-1 and 2-2, in which the oily antibacterial component was not three-phase emulsified, the intraoral dispersibility and retention of the oily antibacterial component were inferior. Moreover, in Comparative Example 2-1, there was almost no effect on inhibition of growth of Candida. In addition, the oral cavity composition of Comparative Example 2-2 was poor in palatability because it consisted of only an oily antibacterial component.

(Examples 3-1 to 3-2 and Comparative Example 3-1)
As the oil phase, antibacterial capric acid (Lunac 10-98, manufactured by Kao Corporation) and medium-chain fatty acid triglyceride (Coconard MT, manufactured by Kao Corporation) of other oil components, water as the aqueous phase, spontaneous closure Using a closed endoplasmic reticulum of decaglyceryl monomyristate (manufactured by Taiyo Kagaku Co., Ltd., Sunsoft Q-14S-C) as a closed endoplasmic reticulum formed by amphipathic substances forming the endoplasmic reticulum, the composition shown in Table 3 ratio (mass %) oral compositions were produced. Specifically, by adding decaglyceryl monomyristate to water while stirring the water, a mixed solution in which a plurality of closed vesicles of decaglyceryl monomyristate are dispersed in water was obtained. Subsequently, while stirring the mixed solution, capric acid having a melting point or higher was added to the mixed solution to obtain an oral composition of Example 3-1. Further, while stirring the mixed solution, capric acid and medium-chain fatty acid triglyceride having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 3-2.

In addition, an oral composition of Comparative Example 3-1 was obtained by adding decaglyceryl monomyristate to water at the composition ratio shown in Table 3 while stirring the water.

The oral compositions obtained in Examples 3-1 and 3-2 and Comparative Example 3-1 were evaluated for their antibacterial activity against Candida (C. albicans strain NBRC1594) in the same manner as in Example 1-1. . Table 3 shows the results of relative values.

As shown in Table 3, similar to the above examples, even in Examples 3-1 and 3-2, in which the oil-based antibacterial component was three-phase emulsified, the growth of Candida was suppressed because of good antibacterial properties. Also, oral compositions stabilized with closed endoplasmic reticulum formed by amphiphiles that spontaneously form closed endoplasmic reticulum showed good antibacterial properties. In addition, since the oil-based antibacterial ingredient was three-phase emulsified, the oil-based antibacterial ingredient had excellent intraoral dispersibility. Further, similarly to the above Examples, the oral compositions of Examples 3-1 and 3-2 were excellent in palatability. On the other hand, Comparative Example 3-1, which does not contain an oil-based antibacterial component, had almost no effect on inhibiting the growth of Candida.

(Examples 4-1 to 4-2 and Comparative Examples 4-1 to 4-2)
As the oil phase, the oily antibacterial component thymol (manufactured by Osaka Kasei Co., Ltd., Japanese Pharmacopoeia product thymol) and other oily component medium-chain fatty acid triglyceride (manufactured by Kao Corporation, Coconard MT), and water and hydroxyl groups as the aqueous phase Using particles of stearoxyhydroxypropyl methylcellulose (Sunjurose 90L, manufactured by Daido Kasei Co., Ltd.) as polycondensation polymer particles, an oral composition having a composition ratio (% by mass) shown in Table 4 was produced. Specifically, by adding particles of stearoxyhydroxypropylmethylcellulose to water while stirring the water, a mixed solution in which a plurality of particles of stearoxyhydroxypropylmethylcellulose are dispersed in water was obtained. Subsequently, while stirring the mixed solution, thymol having a melting point or higher was added to the mixed solution to obtain an oral composition of Example 4-1. Further, while stirring the mixed solution, thymol and medium-chain fatty acid triglycerides having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 4-2.

Also, by mixing thymol, medium-chain fatty acid triglycerides, and water at the composition ratio shown in Table 4, an oral composition of Comparative Example 4-1 was obtained.

In addition, the oral cavity composition of Comparative Example 4-2 was thymol.

Regarding the oral compositions obtained in Examples 4-1 to 4-2 and Comparative Examples 4-1 to 4-2, the antibacterial activity against Candida (C. albicans strain NBRC1594) was evaluated in the same manner as in Example 1-1. evaluated by the method. Table 4 shows the results of relative values.

As shown in Table 4, similar to the above examples, even in Examples 4-1 and 4-2, in which the oil-based antibacterial component was three-phase emulsified, the growth of Candida was suppressed because of good antibacterial properties. In addition, even when the oily antibacterial component was thymol, it exhibited good antibacterial properties. In addition, since the oil-based antibacterial ingredient was three-phase emulsified, the oil-based antibacterial ingredient had excellent intraoral dispersibility. Further, similarly to the above Examples, the oral compositions of Examples 4-1 and 4-2 were excellent in palatability. On the other hand, in Comparative Example 4-1, in which the oil-based antibacterial component was not three-phase emulsified, dispersion was poor due to non-three-phase emulsification, so there was almost no effect on the suppression of Candida growth. In addition, in Comparative Example 4-2, although thymol is inherently antibacterial, it is insoluble in water and thus has little effect on the suppression of Candida growth. In addition, the oral cavity composition of Comparative Example 4-2 was poor in palatability because it consisted of only an oily antibacterial component.

(Example 5-1 and Comparative Example 5-1)
As the oil phase, the oily antibacterial component thymol (manufactured by Osaka Kasei Co., Ltd., Japanese Pharmacopoeia product thymol) and other oily component medium-chain fatty acid triglyceride (manufactured by Kao Corporation, Coconard MT), water as the aqueous phase, polycondensation polymer Using particles of stearoxyhydroxypropyl methylcellulose (manufactured by Daido Kasei Co., Ltd., Sunjurose 90L) as particles, an oral composition having a composition ratio (% by mass) shown in Table 5 was produced. Specifically, by adding particles of stearoxyhydroxypropylmethylcellulose to water while stirring the water, a mixed solution in which a plurality of particles of stearoxyhydroxypropylmethylcellulose are dispersed in water was obtained. Subsequently, while stirring the mixed solution, thymol and medium-chain fatty acid triglyceride having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 5-1.

In addition, the oral cavity composition of Comparative Example 5-1 was thymol.

The oral compositions obtained in Example 5-1 and Comparative Example 5-1 were evaluated for their antibacterial activity against E. coli (E. coli strain NBRC3972) as follows.

Test medium (NBRC802 medium (g / 100 ml), Polypepton 1.0 g, Yeast extract 0.2 g, MgSO ₄ 7H ₂ O 0.2 g) so that the final concentration of the oral composition is 100 μg / ml adjusted to Escherichia coli was added to NBRC802 medium supplemented with the oral composition to 1.0×10 ⁶ cfu/ml. After that, culture was performed at 36° C. for 24 hours.

The turbidity of the suspension was measured using an absorptiometer (wavelength 620 nm). When the turbidity of the culture solution obtained by culturing E. coli in NBRC802 medium without adding the oral cavity composition is set to 100, the relative value of the turbidity of each example and each comparative example was determined. Table 5 shows the results of relative values.

As shown in Table 5, Example 5-1, in which the oil-based antibacterial component was three-phase emulsified, had good antibacterial properties, so that in addition to the Candida fungus, the growth of Escherichia coli could be suppressed. In addition, since the oil-based antibacterial ingredient was three-phase emulsified, the oil-based antibacterial ingredient had excellent intraoral dispersibility. Further, similarly to the above examples, the oral cavity composition of Example 5-1 was excellent in palatability. On the other hand, the oral composition of Comparative Example 5-1 contains antibacterial thymol, but since the oil-based antibacterial component is not three-phase emulsified, it is insoluble in water and thus inhibits the growth of E. coli. had little impact on. In addition, the oral cavity composition of Comparative Example 5-1 was poor in palatability because it consisted of only an oily antibacterial component.

(Examples 6-1 to 6-6)
Antibacterial caprylic acid (Lunac 8-98, manufactured by Kao Corporation) or capric acid (Lunac 10-98, manufactured by Kao Corporation) as the oil phase, water as the aqueous phase, spontaneously forming closed endoplasmic reticulum Pentaglyceryl monomyristate (manufactured by Taiyo Kagaku Co., Ltd., Sunsoft A-141E-C) or decaglyceryl monomyristate (manufactured by Taiyo Kagaku Co., Ltd., Sunsoft Q-14S) as a closed endoplasmic reticulum formed by an amphipathic substance -C,) was used to produce an oral composition having a composition ratio (% by mass) shown in Table 6. Specifically, by adding pentaglyceryl monomyristate or decaglyceryl monomyristate to water while stirring the water, closed endoplasmic reticulum of multiple pentaglyceryl monomyristate or multiple decaglyceryl monomyristate A mixed solution in which the closed endoplasmic reticulum was dispersed in water was obtained. Subsequently, while stirring the mixed solution, caprylic acid or capric acid having a melting point or higher was added to the mixed solution to obtain oral compositions of Examples 6-1 to 6-6. The oral compositions obtained in Examples 6-1 to 6-6 were evaluated for their antibacterial activity against Candida (C. albicans strain NBRC1594) as follows.

Candida (C. albicans strain NBRC1594) was adjusted to 1.0×10 ² cfu/ml in each oral preparation and statically cultured at 30° C. for 48 hours. After that, each was applied to a PDA medium by a plate smearing method, allowed to stand and cultured at 30° C. for 48 hours, and the number of bacteria on the medium was counted to confirm the growth of each Candida fungus. Those in which no colonies were observed on the PDA medium were defined as sterilized, and those in which the number of bacteria did not increase were defined as bacteriostatic.

As shown in Table 6, it was possible to suppress or kill the growth of the oil-based antibacterial component in an amount considerably smaller than any of the amounts used in Tables 1 to 5. In addition, since the oil-based antibacterial ingredient was three-phase emulsified, the oil-based antibacterial ingredient had excellent intraoral dispersibility. In addition, all of them were excellent in palatability because the amount of the antibacterial component was small.

(Example 7-1 and Comparative Examples 7-1 to 7-2)
As the oil phase, antibacterial capric acid (manufactured by Kao Corporation, Lunac 10-98) and medium-chain fatty acid triglyceride (manufactured by Kao Corporation, Coconard MT) of other oil components, water as the aqueous phase, polycondensation polymer An oral composition having a composition ratio (mass %) shown in Table 7 was produced using particles of stearoxyhydroxypropyl methylcellulose (manufactured by Daido Kasei Co., Ltd., Sunjurose 90L). Specifically, by adding particles of stearoxyhydroxypropylmethylcellulose to water while stirring the water, a mixed solution in which a plurality of particles of stearoxyhydroxypropylmethylcellulose are dispersed in water was obtained. Subsequently, while stirring the mixed solution, capric acid and medium-chain fatty acid triglyceride having a melting point or higher were added to the mixed solution to obtain an oral composition of Example 7-1.

Also, water was used as the oral cavity composition of Comparative Example 7-1.

In addition, an oral composition of Comparative Example 7-2 was obtained by using ethanol capable of dispersing capric acid at the composition ratio shown in Table 7 and adding capric acid to ethanol while stirring the ethanol.

The oral compositions obtained in Example 7-1 and Comparative Examples 7-1 and 7-2 were evaluated for their antibacterial action against mycelial Candida in the following manner.

A test medium was prepared with oligotrophic medium, FCS (fetal calf serum) 2.5%, RPMI 1640 medium (1/3 dilution) 32.5%, sterile purified water 65.0%. Next, Candida (C. albicans strain NBRC1594) was added to the nutrient-poor medium to a final concentration of 1.0×10 ⁵ cfu/ml, shake culture was performed at 36° C. for 8 hours, and mycelium-shaped Candida I got the fungus. Next, the oral composition was applied to one side of a sterilized apatite plate (apatite pellet APP-100, manufactured by Cosmo Bio Co., Ltd.) so that the final concentration of the test medium was 1 mg/ml. 150 μl was added dropwise and left for 5 minutes. The same treatment was performed on the surface of the other apatite plate. After that, the surface was lightly washed with purified water. Subsequently, the apatite plate treated with the oral cavity composition was placed on the medium from which the mycelium-shaped Candida was obtained, and shaking culture was performed at 36° C. for 15 hours. After that, it was immersed in 70% ethanol for 1 minute and washed with purified water. Subsequently, 0.01% crystal violet was used to stain Candida on the surface of the apatite plate. Next, the apatite plate was washed with purified water. FIG. 1 is a photograph of the apatite plate stained in Example 7-1 taken with a digital camera. FIG. 2 is a photograph taken with a digital camera of the apatite plate stained in Comparative Example 7-1. FIG. 3 is a photograph taken with a digital camera of the apatite plate stained in Comparative Example 7-2. The greater the amount of Candida fungi present on the surface of the apatite plate, the darker the color of the apatite plate.

As shown in FIGS. 1 to 3 and Table 7, in Example 7-1, in which the oil-based antibacterial component is three-phase emulsified, it has good antibacterial properties, so the apatite plate has a very light color, and the mycelium-shaped Candida fungus growth could be suppressed. In particular, since the emulsified particles formed by three-phase emulsification have a strong adsorptive power to the apatite plate and are difficult to desorb, the emulsified particles containing the oily antibacterial component remain on the surface of the apatite plate even after the apatite plate is washed. , could suppress the growth of mycelial Candida on the surface of the apatite plate. On the other hand, in Comparative Example 7-1, which does not contain an oily antibacterial component, or Comparative Example 7-2, which does not include three-phase emulsification, the color of the apatite plate is dark and does not affect the inhibition of Candida growth. Ta. In particular, in Comparative Example 7-2, the oily antibacterial component was well dispersed in ethanol. However, since the oil-based antibacterial component is molecularly dissolved in ethanol, the oil-based antibacterial component was removed together with the ethanol by washing the apatite plate, and did not remain on the apatite plate. It was comparable to Example 7-1.

Claims

an oil phase containing an oily antibacterial component;
an aqueous phase;
An oral emulsion comprising at least one of closed vesicles formed by an amphiphilic substance that spontaneously forms closed vesicles and particles of a polycondensation polymer having hydroxyl groups, and is an O/W emulsion. Composition.
The composition for oral cavity according to claim 1, wherein the content of said oil phase in said composition for oral cavity is 5.00 × 10 -3 mass% or more and 80.00 mass% or less.
The composition for oral cavity according to claim 1 or 2, wherein the content of said oily antibacterial component in said composition for oral cavity is 5.00 × 10 -3 mass% or more and 10.00 mass% or less.
The oil-based antibacterial ingredients include alkyl fatty acids having 6 to 16 carbon atoms, lower fatty acid monoglycerides, monoterpene hydrocarbons, sesquiterpene hydrocarbons, diterpene hydrocarbons, monoterpene alcohols, and sesquiterpene alcohols having a molecular weight of 600 or less. , diterpene alcohols, phenols, ketones, terpene aldehydes, aliphatic aldehydes, aromatic aldehydes, phenol ethers, lactones, esters, ethers, oxides, carboxylic acids and organic acids An oral composition according to any one of claims 1 to 3, which is one or more selected antimicrobial ingredients.